KURA missed EPS expectations by 86.01%
Mar 05, 2026, 11:39 PM
0.00%
What does KURA do
Kura Oncology, headquartered in San Diego, focuses on developing precision medicines for cancer treatment, including small molecule candidates Ziftomenib, Tipifarnib, and KO-2806. The company went public in November 2015 and employs 142 staff.
Kura Oncology (KURA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Kura Oncology's actual EPS was -$0.92, missing the estimate of -$0.49 per share, resulting in a -86.01% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.